Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | LDHA | P00338 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079950 | 0.86 | LDHA (0.49) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL15797999 | 0.85 | LDHA (0.70) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL24512595 | 0.84 | LDHA (0.58) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL22009959 | 0.84 | LDHA (0.55) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL16209768 | 0.83 | LDHA (0.54) | LDHAMAPTRAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6093737 | 0.81 | CA1 (0.67) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL24512590 | 0.81 | LDHA (0.55) | LDHAMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12312847 | 0.80 | RAB9A (0.50) | LDHAMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1741698 | 0.79 | TP53 (0.54) | CA1CA2LDHAMAPTRAB9A | |
| SCHEMBL20486301 | 0.79 | CA1 (0.41) | CA1CA2LDHAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165780-A1 | CROSSLINKED MATERIALS | FOUNT BIO, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165780-A1 | CROSSLINKED MATERIALS | DCLRE1A, COL2A1, MTCL3 | CA1 1810/4885CA2 2913/4885LDHA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.